Alzheimer’s and Autoimmunity ~ Amyloid-β & Tau ~.

13
Alzheimer’s and Autoimmunity ~ Amyloid-β & Tau ~

Transcript of Alzheimer’s and Autoimmunity ~ Amyloid-β & Tau ~.

Page 1: Alzheimer’s and Autoimmunity ~ Amyloid-β & Tau ~.

Alzheimer’s and Autoimmunity

~ Amyloid-β & Tau ~

Page 2: Alzheimer’s and Autoimmunity ~ Amyloid-β & Tau ~.

Image from http://www.ahaf.org/alzdis/about/AmyloidPlaques.htm

Alzheimer’s Pathologyhttp://www.pathology.vcu.edu/education/cns/lab1.c.html

Page 3: Alzheimer’s and Autoimmunity ~ Amyloid-β & Tau ~.

Amyloid-β Plaques

Amyloid-β protein in a healthy cell

Images from http://www.nursingceu.com/courses/156/index_nceu.html

A-β cleaved by β- & γ-secretases A-β plaque forming outside the cell

Neurofibrillary Tau Tangles

Page 4: Alzheimer’s and Autoimmunity ~ Amyloid-β & Tau ~.

Overexpression of Aβ42 peptide is indicated as a cause of amyloid plaque formation in AD.

The PDAPP mouse overexpresses human Aβ42 and develops many of the neuropathological hallmarks of AD in an age- and brain-region-dependent manner.

What if Aβ42 is presented as an immunogen; does the immune system clear β-amyloid plaques?

Immunization of mice before and after the onset of disease with Aβ42 prevented and reversed the onset of disease (i.e. morbidity, neuritic plaque formation, etc.)

Page 5: Alzheimer’s and Autoimmunity ~ Amyloid-β & Tau ~.

Aβ42 Immunization Prevents β-Amyloid Plaque Development

6 w/o mice

PDAPPPDAPP PDAPPPDAPP

Synthetic human

Aβ42

Peptides from

SAP PBS Buffer Untreated

Mice received 11 immunizations over 11 months.

At 13 months, quantitative immunohistochemical measures determined the extent of amyloid-β burden and the prevalence of neuritic plaques, astrogliosis, and microgliosis.

Experimental Setup

Question: Can immunization of Aβ42 prevent the development of AD-like pathology in young mice?

Page 6: Alzheimer’s and Autoimmunity ~ Amyloid-β & Tau ~.

Aβ42 Immunization Prevents β-Amyloid Plaque DevelopmentResults:Almost complete prevention of amyloid-β deposition.

(1) Quantitative Imaging of Aβ burden in hippocampus: percentage of the area occupied by Aβ deposits.

(2) Aβ deposition, dystrophic neurites, and plaque-associated astrocytosis prevented by Aβ42 immunization

PBS Aβ42

Page 7: Alzheimer’s and Autoimmunity ~ Amyloid-β & Tau ~.

Aβ42 Immunization Slows β-Amyloid Plaque Development

Experimental Setup

11 m/o mice

PDAPP PDAPP

Aβ42 PBS

Mice received several immunizations over the ensuing months.

Half killed at 15 mo. (4 mo. treatment); remaining half killed at 18 mo. (7 mo. treatment).

Brains were examined by image analysis and ELISA to determine the magnitude of amyloid-β burden and the extend of neuritic dystrophy, astrocytosis, and microgliosis.

PDAPP

Untreated

Question: Can immunization of Aβ42 slow the development of AD-like pathology in mice that already show signs of Aβ deposition?

Page 8: Alzheimer’s and Autoimmunity ~ Amyloid-β & Tau ~.

Aβ42 Immunization Slows β-Amyloid Plaque DevelopmentResults:

0.28%

4.87%

0.01%

(3) %-cortical coverage of amyloid-β

12 m/o untreated mouse

18 m/o PBS-immunized

18 m/o Aβ42-immunized

(4) Cortical Aβ deposition

Page 9: Alzheimer’s and Autoimmunity ~ Amyloid-β & Tau ~.

(5) Cortical amyloid-β progression

Retrosplenial Entorhinal

Aβ 42

P

BS

(6) Amyloid-β deposition in molecular layer of the hippocampal dentate gyrus.

Aβ42 Immunization Slows β-Amyloid Plaque DevelopmentResults:

Page 10: Alzheimer’s and Autoimmunity ~ Amyloid-β & Tau ~.

PDAPP-Mouse Aβ42-Immunization Summary

Immunization with Aβ42 preceding plaque development essentially wholly prevents the development of Aβ plaques and associated neuropathology.

Aβ42 injections to mice with developed plaque burden effectively slows the progression of existing pathology, substantially improving Aβ plaque burden, neuritic dystrophy, and gliosis.

The mechanism resulting in plaque reduction did not seem to produce any obvious signs of damage to the neuropil of AB42-immunized mice. Histological examination of several organs, including brain and kidney, revealed no signs of immune-mediated complications, despite high levels of human APP expressed in these tissues and the significant antibody titre to endogenous mouse Aβ peptide (data not shown).

Aβ42 immunization results in the generation of anti-Aβ antibodies and makes Aβ-immunoreactive monocytic/ microglial cells appear in the regions of remaining plaques. Perhaps anti-Aβ Abs facilitate clearance of amyloid-β either before deposition, or after plaque formation, by triggering monocytic/ microglial cells to clear amyloid-β using Fc receptor-mediated signals.

Page 11: Alzheimer’s and Autoimmunity ~ Amyloid-β & Tau ~.

Human Aβ42-Immunization Summary

Neurology, July 2003 Neurology, May 2005

372 participants with mild to moderate AD for IM injections of Aβ42 and placebo (4:1).

6% (18/298) patients treated with Aβ42 developed meningoencephalitis (0/74 on placebo; p = 0.020). 16/18 patients had received 2 doses, one had received 1, and one had received 3 before symptoms occurred.

No case occurred later than 6 months after the first immunization.

Postvaccination meningoencephalitis occurred without clear relation to serum anti-Aβ42 antibody titers. T-cell and/or microglial activation may be causing the inflammation.

Of the 300 Aβ42-treated patients, 59 (19.7%) developed the predetermined Ab response. However, no significant differences were found from placebo groups for all measures except the NTB—neuropsychotolerability. (0.03 +/- 0.37 vs –0.20 +/- 0.45; p = 0.020).

In the small subset of patients who had CSF examinations, CSF tau was decreased in antibody responders (n=11) vs. placebo subjects (n=10; p<0.001).

Page 12: Alzheimer’s and Autoimmunity ~ Amyloid-β & Tau ~.

What about Tau Immunotherapy?

Question:Since Tau tangles are associated with pathology of AD, what happens of we instigate an immune response against Tau?

Answer:Tau vaccination in healthy mice induced AD-like pathology, indicated by neurofibrillary tangles, axonal damage, and gliosis.

Conclusion:Mice AD-like pathologies developed from a immune response against intraneuronal tau. These data implicate an autoimmune mechanism for the development of tau-related abnormalities in AD.

Page 13: Alzheimer’s and Autoimmunity ~ Amyloid-β & Tau ~.

Conclusion

Tau is obviously not a suitable immunogen for AD immunotherapy. We must further explore the relationship between tau autoimmunity and AD pathology. If an autoimmune mechanism for tau-associated microtubule disintegration is discovered, attention can be turned to developing a treatment/cure for this autoimmune response.

Aβ42 is a good target for AD immunotherapy, but much more work needs to be done. Although overwhelmingly successful in a mouse model, the success of Aβ42 injections to human AD patients had unforeseen consequences (6% of people develop CNS inflammation). Furthermore, the efficacy of these clinical trials did not demonstrate great success with various AD indicators.

However, this is not reason to abandon Alzheimer’s immunotherapy research. The challenges of successfully taking a drug from mouse into man are incredible. Future treatments/cures for complex diseases (like Alzheimer’s) will have to be tailored to different subsets of the human population.

A vast majority of patients injected with Aβ42 didn’t develop any negative side effects… patients should be classified and categorized into immune system subsets; i.e., identify a marker indicating a likelihood of inflammation after Aβ42-injection, then only give treatment to people who won’t develop inflammation.